



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/645,895		
				Filing Date	August 21, 2003		
				First Name Inventor	Hoffmann, et al.		
				Group Art Unit	1626-1625		
				Examiner Name	Shameem Golam M- ZNDAVIS		
Sheet 1	of 1	Attorney Docket Number		20693 US3			
U.S. PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
hnd	A1	5,691,336		Dorn et al.	11/25/1997		
hnd	A2	5,972,938		Rupniak et al.	10/26/1999		
hnd	A3	6,297,375		Bos et al.	10/02/2001		
FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>3</sup>
		Office <sup>4</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
hnd	B1		WO 95/16679		Merck & Co.	06/22/1995	
hnd	B2		WO 95/18124		Merck, Sharpe & Dohme	07/06/1995	
hnd	B3		WO 95/23798		Merck & Co.	09/08/1995	
hnd	B4		EP 103 545		F.Hoffmann-La Roche	05/30/2001	
hnd	B5		EP 035 115		F.Hoffmann-La Roche	09/13/2000	
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T <sup>3</sup>
hnd	C1	Hans Bundgaard, <i>Drugs of the Future</i> , Vol. 16(5), pp. 443-458 (1991)					
hnd	C2	Barker, <i>Reviews in the Neurosciences</i> , Vol. 7, No. 3, pp. 187-214 (1996)					
hnd	C3	Longmore et al., <i>Can. J. Physiol. Pharmacol.</i> , Vol. 75, pp. 612-621 (1997)					
hnd	C4	Mark S. Kramer et al., <i>Science</i> , Vol. 281, pp. 1640-1645					
hnd	C5	Maggi et al., <i>J. Auton. Pharmacol.</i> , Vol. 13, pp. 23-93 (1993)					
hnd	C6	Navari et al., <i>The New England Journal of Medicine</i> , Vol. 340, No. 3, pp. 190-195 (1999)					
hnd	C7	Maggi et al., <i>Neuropeptides</i> , Vol. 32(1), pp. 1-49 (1998)					
hnd	C8	Doi et al., <i>European Journal of Pharmacology</i> , Vol. 383(3), pp. 297- 303 (1999)					
hnd	C9	Yoshinori Ikeura et al., <i>Chem. Pharm. Bull.</i> , Vol. 45(10), pp. 1642- 1652 (1997)					
Examiner Signature	Zinnia H Davis					Date Considered:	3/16/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

135987